Elicio Therapeutics (NASDAQ:ELTX) Price Target Raised to $23.00

Elicio Therapeutics (NASDAQ:ELTX) had its price target upped by HC Wainwright from $17.00 to $23.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 54.88% from the company’s current price.

A number of other research analysts also recently weighed in on ELTX. Wall Street Zen downgraded Elicio Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. B. Riley Financial began coverage on Elicio Therapeutics in a research note on Wednesday, June 10th. They issued a “buy” rating and a $27.00 price objective on the stock. LADENBURG THALM/SH SH began coverage on Elicio Therapeutics in a research note on Wednesday, April 15th. They issued a “buy” rating and a $20.00 price objective on the stock. Rodman & Renshaw raised Elicio Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Elicio Therapeutics in a research note on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Elicio Therapeutics has an average rating of “Moderate Buy” and an average target price of $21.75.

Elicio Therapeutics Price Performance

ELTX opened at $14.85 on Monday. The business has a 50-day moving average of $11.36 and a 200-day moving average of $9.96. The company has a debt-to-equity ratio of 5.75, a current ratio of 2.24 and a quick ratio of 2.24. Elicio Therapeutics has a fifty-two week low of $7.37 and a fifty-two week high of $16.00. The company has a market capitalization of $283.43 million, a PE ratio of -6.19 and a beta of 1.13.

Elicio Therapeutics (NASDAQ:ELTX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16). Equities research analysts forecast that Elicio Therapeutics will post -2.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Elicio Therapeutics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 473,859 shares of the company’s stock worth $5,184,000 after buying an additional 19,240 shares during the period. Geode Capital Management LLC increased its position in Elicio Therapeutics by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock worth $1,055,000 after buying an additional 2,832 shares during the period. Renaissance Technologies LLC increased its position in Elicio Therapeutics by 332.7% in the 1st quarter. Renaissance Technologies LLC now owns 121,631 shares of the company’s stock worth $1,300,000 after buying an additional 93,520 shares during the period. Susquehanna International Group LLP increased its position in Elicio Therapeutics by 606.1% in the 3rd quarter. Susquehanna International Group LLP now owns 120,207 shares of the company’s stock worth $1,315,000 after buying an additional 103,184 shares during the period. Finally, Marshall Wace LLP increased its position in Elicio Therapeutics by 35.4% in the 4th quarter. Marshall Wace LLP now owns 117,200 shares of the company’s stock worth $933,000 after buying an additional 30,667 shares during the period. 35.03% of the stock is owned by institutional investors.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.